Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives.

Viruses - 25 Dec 2023

Jin Hongliang, Gong Yani, Cheng Lin, Zhu Yuanmei, Zhang Zheng, He Yuxian

Abstract excerpt

LCB1 is a computationally designed three-helix miniprotein that precisely targets the spike (S) receptor-binding motif (RBM) of SARS-CoV-2, exhibiting remarkable antiviral efficacy; however, emerging SARS-CoV-2 variants could substantially compromise its neutralization effectiveness. In this study, we constructed two multivalent LCB1 fusion proteins termed LCB1T and LCB1T-Fc, and characterized their potency in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to COVID-19
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 38257736
DOI: 10.3390/v16010036
PMCID: PMC10819472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives.PMID 38257736Read ↗

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodiesSemantic proximity Read ↗

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including OmicronSemantic proximity Read ↗

Multivalent designed proteins protect against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1Semantic proximity Read ↗

A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2.Semantic proximity Read ↗

Designed miniproteins potently inhibit and protect against MERS-CoVSemantic proximity Read ↗

Broad-spectrum coronavirus neutralization induced by hetero RBD-Fc protein vaccineSemantic proximity Read ↗

A macrocyclic peptide-based fusion inhibitor targeting SARS-CoV-2 Spike S2 subunitSemantic proximity Read ↗

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesSemantic proximity Read ↗

Designed miniproteins potently inhibit and protect against MERS-CoVSemantic proximity Read ↗

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionSemantic proximity Read ↗

Discovery of highly potent small molecule pan-coronavirus fusion inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.